(Q38775281)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Grant McArthur

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Miles C Andrews

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Richard F. Kefford

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Georgina V. Long

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

John J Park

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jonathan Cebon

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Alexander M Menzies

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

19

Matteo S Carlino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

4

Rajat Rai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

11

Andrew Haydon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Sagun Parakh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Shehara Mendis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Wen Xu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Martin Drummond

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Catherine Rowe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Annie Wong

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Alex Guminski

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Oliver Klein

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

18 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

1558-1563

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

20 March 2020

copyright license

start time

18 May 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Pembrolizumab versus Ipilimumab in Advanced Melanoma

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Nivolumab in previously untreated melanoma without BRAF mutation

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Systemic treatment for BRAF-mutant melanoma: where do we go next?

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Combining radiotherapy and cancer immunotherapy: a paradigm shift

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Treatment of melanoma brain metastases: a new paradigm.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Determinants of outcome in melanoma patients with cerebral metastases

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

15 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5518864

The radioresponsiveness of melanoma

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2017.142

inferred from DOI database lookup

7 January 2021

based on heuristic

Immune effects of targeted radiation therapy for cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28524161

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2017.142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28524161%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

28524161

1 reference